CR20160477A - Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso - Google Patents
Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y usoInfo
- Publication number
- CR20160477A CR20160477A CR20160477A CR20160477A CR20160477A CR 20160477 A CR20160477 A CR 20160477A CR 20160477 A CR20160477 A CR 20160477A CR 20160477 A CR20160477 A CR 20160477A CR 20160477 A CR20160477 A CR 20160477A
- Authority
- CR
- Costa Rica
- Prior art keywords
- nanoparticles
- elaboration
- therapeutic
- methods
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
La presente divulgación generalmente se refiere a nanopartículas que comprenden un ácido sustancialmente hidrófobo y un agente terapéutico (1¿(4¿{[4¿(dimetilamino)piperidin¿1¿il]carbonil}fenil)¿3¿[4¿(4,6¿dimorfolin¿4¿il¿1,3,5¿triazin¿2¿il)fenil]urea), o sus sales farmacéuticamente aceptables y un polímero. Otros aspectos incluyen métodos de elaboración y uso de dichas nanopartículas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461953628P | 2014-03-14 | 2014-03-14 | |
PCT/US2015/020343 WO2015138835A1 (en) | 2014-03-14 | 2015-03-13 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160477A true CR20160477A (es) | 2017-02-24 |
Family
ID=52780047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160477A CR20160477A (es) | 2014-03-14 | 2015-03-13 | Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso |
Country Status (42)
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
JP6573895B2 (ja) * | 2014-02-13 | 2019-09-11 | ファイザー・インク | 治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法 |
JP6753843B2 (ja) | 2014-05-14 | 2020-09-16 | タルグルムーネ セラピウティクス エージー | 改善されたポリエチレンイミンポリエチレングリコールベクター |
MX2017008072A (es) * | 2014-12-17 | 2017-09-28 | Pfizer | Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. |
WO2017062920A1 (en) * | 2015-10-07 | 2017-04-13 | Chopra Sunandini | Nanoparticles with ph triggered drug release |
RU2018115566A (ru) * | 2015-10-30 | 2019-12-03 | Пфайзер Инк. | Терапевтические наночастицы, содержащие терапевтический агент, и их способы получения и применения |
JP2019512516A (ja) * | 2016-03-25 | 2019-05-16 | ファイザー・インク | 治療用粒子を凍結乾燥するための安定した製剤 |
US10369230B2 (en) | 2017-04-06 | 2019-08-06 | National Guard Health Affairs | Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy |
HRP20211985T1 (hr) | 2017-08-25 | 2022-04-01 | Pfizer Inc. | Farmaceutska vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu |
RS64692B1 (sr) * | 2018-06-07 | 2023-11-30 | Pfizer | Vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu |
CN111286204B (zh) * | 2020-03-12 | 2021-08-20 | 复旦大学 | 一种遇含水溶剂快速溶解或分散的高分子复合物及其制备方法和应用 |
RU2751699C1 (ru) * | 2020-07-17 | 2021-07-15 | Федеральное казённое учреждение здравоохранения "Ставропольский научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ получения наночастиц хитозана с включенным ципрофлоксацином |
CA3192963A1 (en) | 2020-10-08 | 2022-04-14 | Esteban Pombo-Villar | Immunotherapy for the treatment of cancer |
US20230022525A1 (en) | 2021-07-26 | 2023-01-26 | Celcuity Inc. | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
WO2023079142A2 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2023150246A1 (en) * | 2022-02-04 | 2023-08-10 | Virginia Commonwealth University | Sustained release formulations and methods of use thereof |
US11833224B1 (en) | 2023-02-08 | 2023-12-05 | Leuvian Llc | Lyoprotectant compositions and uses thereof |
Family Cites Families (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0394265B1 (en) | 1987-07-29 | 1994-11-02 | The Liposome Company, Inc. | Method for size separation of particles |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
US5563122A (en) | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
WO1996028143A1 (de) | 1995-03-10 | 1996-09-19 | Boehringer Mannheim Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
US6902743B1 (en) | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
FR2742357B1 (fr) * | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
JP2942508B2 (ja) | 1997-01-14 | 1999-08-30 | 順也 藤森 | 温度感受性徐放性基剤及び温度感受性徐放性システム |
US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6254890B1 (en) | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
JP2002519333A (ja) | 1998-06-30 | 2002-07-02 | アムジエン・インコーポレーテツド | 生物学的に活性な物質の徐放運搬のための感熱性生分解性ヒドロゲル |
US6265609B1 (en) | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
KR100274842B1 (ko) | 1998-10-01 | 2001-03-02 | 김효근 | 미립구를 이용한 레티노익산의 서방형 약물방출 시스템 |
DE19856432A1 (de) | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
CA2321321A1 (en) | 1999-09-30 | 2001-03-30 | Isotis B.V. | Polymers loaded with bioactive agents |
US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
US6890946B2 (en) | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
US7217770B2 (en) | 2000-05-17 | 2007-05-15 | Samyang Corporation | Stable polymeric micelle-type drug composition and method for the preparation thereof |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
KR100418916B1 (ko) | 2000-11-28 | 2004-02-14 | 한국과학기술원 | 생분해성 고분자와 항암제의 접합체를 이용한 서방형미셀제제의 제조방법 |
KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
EP1343480B2 (en) | 2000-12-21 | 2016-02-17 | Alrise Biosystems GmbH | Induced phase transition method for the production of microparticles containing hydrophobic active agents |
US6623761B2 (en) | 2000-12-22 | 2003-09-23 | Hassan Emadeldin M. | Method of making nanoparticles of substantially water insoluble materials |
EP1345597B1 (en) | 2000-12-27 | 2007-10-03 | Ares Trading S.A. | Amphiphilic lipid nanoparticles for peptide and/or protein incorporation |
CA2436408A1 (en) | 2001-02-07 | 2002-12-12 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
AU2002338336A1 (en) | 2001-04-03 | 2002-10-21 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
AU2002322295C1 (en) | 2001-06-21 | 2008-12-18 | Altus Pharmaceuticals Inc. | Spherical protein particles and methods of making and using them |
US7498045B2 (en) | 2001-08-31 | 2009-03-03 | Thomas M. S. Chang | Biodegradable polymeric nanocapsules and uses thereof |
US6592899B2 (en) | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
BRPI0213226B1 (pt) | 2001-10-10 | 2016-03-01 | Pf Medicament | processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princípio ativo hidrossolúvel, e, microesferas |
ES2625340T3 (es) | 2001-10-15 | 2017-07-19 | Crititech, Inc. | Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento |
US20030235619A1 (en) | 2001-12-21 | 2003-12-25 | Christine Allen | Polymer-lipid delivery vehicles |
US20060177495A1 (en) | 2001-12-21 | 2006-08-10 | Christine Allen | Polymer-lipid delivery vehicles |
US7408079B2 (en) | 2002-01-10 | 2008-08-05 | The Johns Hopkins University | Imaging agents and methods of imaging NAALADase or PSMA |
AU2003227147A1 (en) | 2002-04-05 | 2003-10-27 | Universite De Montreal | Stealthy polymeric biodegradable nanospheres and uses thereof |
US20030232887A1 (en) | 2002-04-10 | 2003-12-18 | Johnson Douglas Giles | Preparation and use of a stable formulation of allosteric effector compounds |
AU2003228666A1 (en) | 2002-04-23 | 2003-11-10 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
WO2003103549A1 (en) | 2002-06-05 | 2003-12-18 | University Of Florida | Ophthalmic drug delivery system |
US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
US7879351B2 (en) | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
JP2006514698A (ja) | 2002-10-30 | 2006-05-11 | スフェリックス, インコーポレイテッド | ナノ粒子生物活性物質 |
AU2003293195A1 (en) | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US6841547B2 (en) | 2003-02-28 | 2005-01-11 | Albert Einstein College Of Medicine Of Yeshevia University | Method for decreasing low density lipoprotein |
US20040185170A1 (en) | 2003-03-21 | 2004-09-23 | Shubha Chungi | Method for coating drug-containing particles and formulations and dosage units formed therefrom |
US20060233883A1 (en) | 2003-03-26 | 2006-10-19 | Tsutomu Ishihara | Intravenous nanoparticles for targeting drug delivery and sustained drug release |
JP4989217B2 (ja) | 2003-03-26 | 2012-08-01 | エガレット エイ/エス | 薬剤物質の送達制御用マトリックス組成物 |
AU2004228008B2 (en) | 2003-04-03 | 2008-11-06 | Jessie L.-S. Au | Tumor-targeting drug-loaded particles |
US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
US20050256071A1 (en) | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
BRPI0412211A (pt) | 2003-07-23 | 2006-08-22 | Pr Pharmaceuticals Inc | composições de liberação controlada |
WO2005020989A1 (en) | 2003-09-02 | 2005-03-10 | Novartis Ag | Cancer treatment with epothilones |
US7311901B2 (en) | 2003-10-10 | 2007-12-25 | Samyang Corporation | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery |
US7846412B2 (en) | 2003-12-22 | 2010-12-07 | Emory University | Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof |
AU2005219413A1 (en) | 2004-03-02 | 2005-09-15 | Massachusetts Institute Of Technology | Nanocell drug delivery system |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
US8043631B2 (en) | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
WO2006002365A2 (en) | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
CA2571899A1 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
JP2006131577A (ja) | 2004-11-09 | 2006-05-25 | Ltt Bio-Pharma Co Ltd | 異なる粒子径を有する薬物封入ナノ粒子の作製方法および当該方法で得られたナノ粒子 |
AU2005321543A1 (en) | 2004-12-30 | 2006-07-06 | Cinvention Ag | Combination comprising an agent providing a signal, an implant material and a drug |
WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
EP2298318A1 (en) | 2005-04-04 | 2011-03-23 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
JP2006321763A (ja) | 2005-05-20 | 2006-11-30 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | 生体適合性ナノ粒子及びその製造方法 |
CA2611985C (en) | 2005-06-17 | 2016-08-16 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
PE20100809A1 (es) | 2005-07-11 | 2011-01-07 | Wyeth Llc | Inhibidores de glutamato de metaloproteinasas de matriz y agrecanasas |
NZ623901A (en) | 2005-08-03 | 2015-10-30 | Immunogen Inc | Immunoconjugate formulations |
US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
JP2009507049A (ja) | 2005-09-09 | 2009-02-19 | 北京徳科瑞医薬科技有限公司 | リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤 |
US20090022806A1 (en) | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
CA2623293A1 (en) | 2005-09-20 | 2007-03-29 | Shimon Benita | Nanoparticles for targeted delivery of active agents |
ES2564241T3 (es) | 2005-12-02 | 2016-03-21 | Glaxosmithkline Biologicals Sa | Nanopartículas para su uso en composiciones inmunogénicas |
US8916206B2 (en) | 2005-12-26 | 2014-12-23 | Ltt Bio-Pharma Co., Ltd. | Nanoparticles containing water-soluble non-peptide low-molecular weight drug |
US7842312B2 (en) | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
WO2007101111A2 (en) | 2006-02-23 | 2007-09-07 | Erimos Pharmaceuticals Llc | Methods of treating influenza viral infections |
DE102006013531A1 (de) | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Polylactid-Nanopartikel |
ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
WO2007133807A2 (en) | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
SI2049142T2 (sl) | 2006-07-26 | 2016-04-29 | Sandoz Ag | Formulacije kaspofungina |
CA2659687A1 (en) | 2006-07-31 | 2008-02-07 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparation containing amide compound |
CA2659330A1 (en) | 2006-07-31 | 2008-02-07 | Neurosystec Corporation | Nanoparticle drug formulations |
US20100144845A1 (en) | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
US9248121B2 (en) | 2006-08-21 | 2016-02-02 | Abbott Laboratories | Medical devices for controlled drug release |
WO2008038944A1 (en) | 2006-09-26 | 2008-04-03 | Samyang Corporation | Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof |
CN101778910B (zh) | 2006-11-08 | 2014-05-28 | 分子制药洞察公司 | 谷氨酸的异质二聚体 |
US20100303723A1 (en) | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
CN1957911A (zh) | 2006-12-01 | 2007-05-09 | 济南康泉医药科技有限公司 | 一种抗实体肿瘤缓释剂 |
CN101396340A (zh) | 2006-12-12 | 2009-04-01 | 济南帅华医药科技有限公司 | 一种含埃坡霉素衍生物的抗癌缓释注射剂 |
CN101433520A (zh) | 2006-12-12 | 2009-05-20 | 济南帅华医药科技有限公司 | 含埃坡霉素的抗癌缓释剂 |
CN1969816A (zh) | 2006-12-12 | 2007-05-30 | 济南帅华医药科技有限公司 | 一种含埃坡霉素的抗癌缓释剂 |
CN101396342A (zh) | 2006-12-12 | 2009-04-01 | 济南帅华医药科技有限公司 | 含埃坡霉素衍生物的抗癌缓释注射剂 |
CN1969818A (zh) | 2006-12-12 | 2007-05-30 | 济南帅华医药科技有限公司 | 一种含埃坡霉素衍生物的抗癌缓释注射剂 |
CN1961864A (zh) | 2006-12-12 | 2007-05-16 | 济南帅华医药科技有限公司 | 一种抗癌的组合物 |
US20100015050A1 (en) | 2006-12-21 | 2010-01-21 | Wayne State University | Peg and targeting ligands on nanoparticle surface |
DK2481409T3 (en) | 2007-03-07 | 2018-08-06 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
CN101053553B (zh) | 2007-03-16 | 2011-04-20 | 吉林大学 | 一种生物可降解氟尿嘧啶聚酯载药纳米球及其制备方法 |
EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
JP2010523595A (ja) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ(アミノ酸)ターゲッティング部分 |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
US20100129456A1 (en) | 2007-05-14 | 2010-05-27 | Ltt Bio-Pharma Co., Ltd. | Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group |
EP2187968A4 (en) | 2007-08-21 | 2013-02-20 | Univ Texas | THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS |
US20090061009A1 (en) | 2007-08-29 | 2009-03-05 | Joseph Schwarz | Composition and Method of Treatment of Bacterial Infections |
US20090306120A1 (en) | 2007-10-23 | 2009-12-10 | Florencia Lim | Terpolymers containing lactide and glycolide |
US8974814B2 (en) | 2007-11-12 | 2015-03-10 | California Institute Of Technology | Layered drug delivery polymer monofilament fibers |
WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
WO2009084801A1 (en) | 2007-12-31 | 2009-07-09 | Samyang Corporation | Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same |
EP2106806A1 (en) | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
CN102215830A (zh) * | 2008-05-06 | 2011-10-12 | 葛兰素集团有限公司 | 生物活性剂的囊封方法 |
US20090312402A1 (en) | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
GEP20125589B (en) | 2008-05-23 | 2012-07-25 | Wyeth Llc | TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS |
AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
CN102099016A (zh) * | 2008-06-16 | 2011-06-15 | 佰恩德生物科学股份有限公司 | 载药的聚合物纳米微粒及其制备和使用方法 |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
JP2012501966A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法 |
EP2285350B1 (en) | 2008-06-16 | 2017-11-15 | Pfizer Inc | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles |
TW201014602A (en) | 2008-07-08 | 2010-04-16 | Abbott Lab | Prostaglandin E2 binding proteins and uses thereof |
WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
US20110125090A1 (en) | 2008-11-13 | 2011-05-26 | Peyman Gholam A | Ophthalmic drug delivery system and method |
WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
JP2012522055A (ja) | 2009-03-30 | 2012-09-20 | セルリアン・ファーマ・インコーポレイテッド | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
WO2010114770A1 (en) | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
WO2010114768A1 (en) | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
AU2010254180B2 (en) | 2009-05-27 | 2015-08-27 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
WO2011060328A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
ES2721898T3 (es) | 2009-12-11 | 2019-08-06 | Pfizer | Formulaciones estables para liofilizar partículas terapéuticas |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
WO2011084513A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
JP5898627B2 (ja) | 2009-12-15 | 2016-04-06 | バインド セラピューティックス インコーポレイテッド | エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法 |
CN102740895B (zh) | 2009-12-23 | 2016-02-24 | 伊利诺伊大学董事会 | 纳米轭合物以及纳米轭合物配制品 |
WO2011119995A2 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
WO2012040513A1 (en) | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for the delivery of beta lapachone |
US20150056300A1 (en) | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
WO2013044219A1 (en) | 2011-09-22 | 2013-03-28 | Bind Biosciences | Methods of treating cancers with therapeutic nanoparticles |
AU2013208323B2 (en) | 2012-01-13 | 2017-07-06 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
WO2013127490A1 (de) | 2012-02-29 | 2013-09-06 | Merck Patent Gmbh | Verfahren zur herstellung wirkstoffbeladener nanopartikel |
NZ705985A (en) | 2012-09-17 | 2018-08-31 | Pfizer | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
CN104812381B (zh) | 2012-09-17 | 2018-01-26 | 辉瑞大药厂 | 用于制备治疗性纳米颗粒的方法 |
JP2016523915A (ja) | 2013-06-28 | 2016-08-12 | バインド セラピューティックス インコーポレイテッド | ドセタキセルポリマーナノ粒子及びそれを使用する癌の治療方法 |
-
2015
- 2015-03-13 SG SG11201607645TA patent/SG11201607645TA/en unknown
- 2015-03-13 TW TW107122281A patent/TWI693937B/zh not_active IP Right Cessation
- 2015-03-13 AP AP2016009494A patent/AP2016009494A0/en unknown
- 2015-03-13 CU CU2016000135A patent/CU24488B1/es unknown
- 2015-03-13 CN CN201580013968.0A patent/CN106163503B/zh not_active Expired - Fee Related
- 2015-03-13 TW TW104108222A patent/TWI636798B/zh not_active IP Right Cessation
- 2015-03-13 GE GEAP201514297A patent/GEP20207083B/en unknown
- 2015-03-13 RS RS20190934 patent/RS59035B9/sr unknown
- 2015-03-13 EA EA201691692A patent/EA032234B1/ru unknown
- 2015-03-13 HU HUE15713285A patent/HUE043964T2/hu unknown
- 2015-03-13 MY MYPI2016703352A patent/MY178189A/en unknown
- 2015-03-13 ME MEP-2019-192A patent/ME03435B/me unknown
- 2015-03-13 MA MA39734A patent/MA39734B1/fr unknown
- 2015-03-13 UA UAA201609702A patent/UA121967C2/uk unknown
- 2015-03-13 DK DK15713285.3T patent/DK3116547T3/da active
- 2015-03-13 AU AU2015229210A patent/AU2015229210B2/en not_active Ceased
- 2015-03-13 SI SI201530812T patent/SI3116547T1/sl unknown
- 2015-03-13 LT LTEP15713285.3T patent/LT3116547T/lt unknown
- 2015-03-13 PL PL15713285T patent/PL3116547T3/pl unknown
- 2015-03-13 KR KR1020167028488A patent/KR20160126084A/ko active IP Right Grant
- 2015-03-13 EP EP15713285.3A patent/EP3116547B1/en active Active
- 2015-03-13 AR ARP150100770A patent/AR099756A1/es unknown
- 2015-03-13 CR CR20160477A patent/CR20160477A/es unknown
- 2015-03-13 WO PCT/US2015/020343 patent/WO2015138835A1/en active Application Filing
- 2015-03-13 BR BR112016021130A patent/BR112016021130A2/pt not_active Application Discontinuation
- 2015-03-13 CA CA2942859A patent/CA2942859A1/en not_active Abandoned
- 2015-03-13 PE PE2016001610A patent/PE20170312A1/es unknown
- 2015-03-13 ES ES19156064T patent/ES2834927T3/es active Active
- 2015-03-13 EP EP19156064.8A patent/EP3511019B1/en active Active
- 2015-03-13 DK DK19156064.8T patent/DK3511019T3/da active
- 2015-03-13 MX MX2016012009A patent/MX2016012009A/es unknown
- 2015-03-13 JP JP2016575625A patent/JP6348616B2/ja not_active Expired - Fee Related
- 2015-03-13 PT PT15713285T patent/PT3116547T/pt unknown
- 2015-03-13 US US14/656,899 patent/US9895378B2/en active Active
- 2015-03-13 ES ES15713285T patent/ES2737692T3/es active Active
-
2016
- 2016-08-18 IL IL247346A patent/IL247346B/en active IP Right Grant
- 2016-09-08 SA SA516371814A patent/SA516371814B1/ar unknown
- 2016-09-13 NI NI201600138A patent/NI201600138A/es unknown
- 2016-09-14 SV SV2016005277A patent/SV2016005277A/es unknown
- 2016-09-14 CL CL2016002308A patent/CL2016002308A1/es unknown
- 2016-09-14 PH PH12016501794A patent/PH12016501794A1/en unknown
- 2016-09-14 DO DO2016000244A patent/DOP2016000244A/es unknown
- 2016-09-26 ZA ZA2016/06646A patent/ZA201606646B/en unknown
- 2016-10-14 EC ECIEPI201681557A patent/ECSP16081557A/es unknown
-
2018
- 2018-01-03 US US15/860,881 patent/US10071100B2/en active Active
- 2018-05-31 JP JP2018104561A patent/JP2018154643A/ja not_active Withdrawn
- 2018-08-02 US US16/053,347 patent/US20180344746A1/en not_active Abandoned
-
2019
- 2019-07-01 HR HRP20191187TT patent/HRP20191187T1/hr unknown
- 2019-07-05 CY CY20191100714T patent/CY1122078T1/el unknown
- 2019-10-04 AU AU2019240695A patent/AU2019240695A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/183,596 patent/US20210177857A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20160477A (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso | |
UY37036A (es) | Compuestos inhibidores de la quinasa de unión a tank | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
ECSP15013179A (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas | |
CL2016001895A1 (es) | Compuestos | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
WO2014194254A8 (en) | Treatment of cancers using pi3 kinase isoform modulators | |
MX2016014320A (es) | Composiciones de suspension de liberacion prolongada. | |
CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
GT201600050A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso | |
CL2015002346A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
CL2014003148A1 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición. | |
BR112017028468A2 (pt) | formulação sólida oral, e método para preparar uma formulação sólida oral | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
BR112018006870A2 (pt) | nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas | |
ECSP16086196A (es) | Sales farmacéuticamente aceptables de enantiomeros de pirlindole para uso en medicina | |
IT201600081379A1 (it) | Composizione farmaceutica per uso nel trattamento delle patologie prostatiche. | |
BR112017006918A2 (pt) | formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares | |
FR3045392B1 (fr) | Dispositif pour le traitement d'un sujet par combinaison notamment de la lithotherapie, la chromotherapie, la luminotherapie et la musicotherapie | |
CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
ITUB20161016A1 (it) | Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi |